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Abstract
Background: Campylobacter jejuni is the predominant cause of antecedent infection in post-infectious
neuropathies such as the Guillain-Barré (GBS) and Miller Fisher syndromes (MFS). GBS and MFS are
probably induced by molecular mimicry between human gangliosides and bacterial lipo-oligosaccharides
(LOS). This study describes a new C. jejuni-specific high-throughput AFLP (htAFLP) approach for detection
and identification of DNA polymorphism, in general, and of putative GBS/MFS-markers, in particular.
Results: We compared 6 different isolates of the "genome strain" NCTC 11168 obtained from different
laboratories. HtAFLP analysis generated approximately 3000 markers per stain, 19 of which were
polymorphic. The DNA polymorphisms could not be confirmed by PCR-RFLP analysis, suggesting a
baseline level of 0.6% AFLP artefacts. Comparison of NCTC 11168 with 4 GBS-associated strains revealed
23 potentially GBS-specific markers, 17 of which were identified by DNA sequencing. A collection of 27
GBS/MFS-associated and 17 enteritis control strains was analyzed with PCR-RFLP tests based on 11 of
these markers. We identified 3 markers, located in the LOS biosynthesis genes cj1136, cj1138 and cj1139c,
that were significantly associated with GBS (P = 0.024, P = 0.047 and P < 0.001, respectively). HtAFLP
analysis of 13 highly clonal South African GBS/MFS-associated and enteritis control strains did not reveal
GBS-specific markers.
Conclusion: This study shows that bacterial GBS markers are limited in number and located in the LOS
biosynthesis genes, which corroborates the current consensus that LOS mimicry may be the prime
etiologic determinant of GBS. Furthermore, our results demonstrate that htAFLP, with its high
reproducibility and resolution, is an effective technique for the detection and subsequent identification of
putative bacterial disease markers.
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Background
The Guillain-Barré syndrome (GBS) is the most frequent
form of acute immune-mediated neuropathy. The Miller
Fisher syndrome (MFS) is a variant of GBS, affecting
mainly the eye muscles [1]. A respiratory or gastro-intesti-
nal infection preceding the neurological symptoms is
reported by nearly two-thirds of all patients [2]. The most
frequently identified infectious agent is Campylobacter
jejuni, which is also the predominant cause of bacterial
diarrhoea worldwide [3,4]. The neuropathy is probably
induced by molecular mimicry between gangliosides in
nerve tissue and lipo-oligosaccharides (LOS) on the
Campylobacter cell surface [5]. This structural resemblance
leads to a cross-reactive immune response causing neuro-
logical damage. Biochemical and serological studies have
revealed that many C. jejuni strains express ganglioside-
like structures in their LOS [6]. However, not all strains
expressing ganglioside mimics induce GBS. It is estimated
that only 1 in every 1000–3000 C. jejuni infections is fol-
lowed by GBS [7,8], which suggests that additional bacte-
rial determinants and/or host-related factors are
important as well.
Many researchers have studied collections of GBS-associ-
ated and control "enteritis-only" strains in search of GBS-
specific microbial features. Several reports describe an
overrepresentation of specific Penner (heat stable, HS)
serotypes among GBS-associated strains from certain geo-
graphical areas [9,10]. The HS:19 and HS:41 serotypes are
the predominant serotypes preceding GBS in Japan and
South Africa, respectively [9,10]. Because HS:19 and
HS:41 strains represent a clonal population [11,12], the
observed overrepresentation of these serotypes does not
imply that the determinant of the Penner serotyping sys-
tem, the capsular polysaccharide, is involved in the patho-
genesis of GBS [13]. In addition, this phenomenon is not
seen in other regions, where GBS-associated strains are
genetically heterogeneous [14]. Various molecular typing
techniques have been used in search of GBS-specific fea-
tures in C. jejuni, such as flaA-PCR-restriction fragment
length polymorphism (RFLP), pulsed field gel electro-
phoresis (PFGE), randomly amplified polymorphic DNA
(RAPD) analysis, ribotyping, amplified fragment length
polymorphism (AFLP) analysis and multi locus sequence
typing (MLST), but none of these have identified GBS-spe-
cific markers [14-17]. Very recently, Leonard et al. also
failed to detect GBS-specific features by the use of an open
reading frame (ORF)-specific C. jejuni DNA microarray
[18]. However, this array was based on the genome
sequence of strain NCTC 11168 and ORFs that are not
present in this strain will not be detected. In addition, pos-
sible GBS-factors other than those relating to presence or
absence of certain genes will not be detected using this
approach. Based on the molecular mimicry hypothesis,
other researchers focused on genes involved in LOS bio-
synthesis and found significant associations with GBS
[19-22]. However, these associations are not absolute and
the question remains whether other GBS-specific micro-
bial factors, either LOS-related or not, may exist.
Comparative genomics technology facilitates genetic
marker identification but not all methods may be equally
suited for high-throughput marker searches. Molecular
typing techniques for Campylobacter strains differ in sensi-
tivity and the overall coverage of genome regions
screened. For the detection of specific disease markers it is
desirable to use a technique that screens diversity in the
overall genome with a very high resolution. MLST and
flaA PCR-RFLP analyze restricted parts of the genome and
are not suitable for the detection of additional GBS-mark-
ers [23,24]. PFGE is based on digestion of genomic DNA
with a rare cutting restriction enzyme and only large inser-
tions or deletions and mutations in the restriction sites
will be detected [14]. PFGE patterns normally display
between 10 and 20 fragments, which covers 120 nucle-
otides when a six nucleotide restriction enzyme recogni-
tion sequence is involved. AFLP analysis is considerably
more sensitive than PFGE for the detection of DNA
sequence polymorphism. In a conventional AFLP analy-
sis, the use of two restriction enzymes and a primer pair
with 1 or 2 selective nucleotides leads to a DNA finger-
print pattern consisting of approximately 50–80 frag-
ments per strain. This approach physically covers in the
order of 600–1000 nucleotides of the total genome for
sequence polymorphism [25]. Even the use of two restric-
tion enzymes in PFGE will not make up for the difference
observed under a single AFLP reaction. As indicated
above, DNA microarrays cover the full genome but will
only detect differences in the presence of known genes.
Recently, we described a new high throughput AFLP
(htAFLP) approach for the identification of DNA poly-
morphism in Mycobacterium tuberculosis [26]. This method
has the capacity to detect mutations in more than 30,000
nucleotides scattered throughout the genome, depending
on the number of restriction enzymes and primer pairs
used. The choice of primers and restriction enzymes is cru-
cial and selection of these requires close attention. A
wrong choice may lead to crowding of amplified frag-
ments, caused by limiting (limited?) resolution of the gel-
system. Correct, computer-mediated comparison of AFLP
fingerprints may then be compromised. However, espe-
cially the enhanced resolution makes htAFLP an excellent
candidate technique for the detection of potential disease-
associated markers.
The main objective of the current study was to search an
elaborate collection of C. jejuni stains isolated from GBS
patients for genetic markers associated with bacterial neu-
ropathogenicity. To this aim, we developed htAFLP for C.
jejuni. We analyzed six isolates of strain NCTC 11168, theBMC Microbiology 2006, 6:32 http://www.biomedcentral.com/1471-2180/6/32
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"genome" strain, obtained from different laboratories,
with the aim to detect base-level polymorphism intro-
duced by sub-culturing or storage. In search of potential
GBS-specific markers, we compared the NCTC 11168
AFLP patterns with those of four GBS-associated strains.
In addition, we analyzed a collection of highly clonal
GBS-associated and control strains from South Africa.
Potential GBS-specific htAFLP markers were further iden-
tified by DNA sequencing and PCR-RFLP tests were devel-
oped. These PCR-RFLP tests were used to screen a larger
collection of GBS-associated and control strains for confir-
mation of the potential GBS markers.
Results
Detection and identification of DNA sequence 
polymorphism in NCTC 11168 strains of diverse origin
HtAFLP analysis of C. jejuni was performed with one
enzyme combination. Genomic DNA was digested with
MboI and DdeI and the restricted DNA was amplified by
using all 64 possible combinations of +1/+2 selective
primer pairs. This resulted in the generation of approxi-
mately 3000 fragments per strain. The average fragment
size was 243 basepairs (bp), ranging from 46 to 613 bp.
Comparative htAFLP analysis of the six NCTC 11168 iso-
lates revealed 19 polymorphic fragments. After excision
from the gel, these fragments were amplified and the DNA
sequences were determined. BLAST analysis of the DNA
sequences resulted in the identification of 13/19 poly-
morphisms, which were spread throughout the genome
(Table 1). For the other polymorphic fragments, repeated
amplification and sequencing failed to generate DNA
sequences of sufficient quality for BLAST analysis.
Validation of NCTC 11168 polymorphism with a PCR-
RFLP approach
To verify whether the htAFLP-polymorphic fragments rep-
resent true DNA sequence polymorphism, we analyzed
the six NCTC 11168 isolates by PCR-RFLP analysis. An
AFLP polymorphism that is based on mutations in the
restriction site will result in a polymorphic RFLP pattern,
whereas insertions or deletions in the AFLP fragment will
result in size differences between the PCR products. Based
on the BLAST hit sequences (Table 1), PCR tests for ampli-
fying twelve marker fragments and their flanking regions
were developed. Fragments of correct size were produced
with all primer sets and for all isolates (results not
shown). Next, PCR products of the six NCTC 11168
strains were digested in separate reactions with the AFLP
restriction enzymes (results not shown). None of the
digests showed polymorphic RFLP patterns. Thus, restric-
tion site polymorphism or insertions/deletions could not
be confirmed as cause of the observed AFLP polymor-
phisms. Nine out of twelve (75%) digests with DdeI and
six of twelve (50%) digests with MboI resulted in RFLP
patterns as expected based on the NCTC 11168 DNA
sequence. An AFLP polymorphism can also be the result
of a mutation in the nucleotides complementary to the
selective primer nucleotides. Because all 64 possible com-
binations of the +1/+2 primer pairs were used in this
htAFLP, such a mutation would be expected to result in an
additional polymorphism, with the same fragment length
and localization on the genome, in the AFLP pattern gen-
erated with a different primer pair. We did not detect such
complementary polymorphisms in the NCTC 11168
comparison. In conclusion, the polymorphic AFLP bands
observed in the NCTC 11168 comparison, representing
approximately 0.6% of all bands, probably represent the
low "background noise" of the htAFLP technique.
Comparison of NCTC 11168 with GBS-associated strains 
for the detection and identification of potential markers 
for GBS
For the detection of putative markers for the Guillain-
Barré syndrome, we compared the NCTC 11168 isolates
with strain GB11, which was isolated from a GBS patient.
Strain NCTC 11168 was originally isolated from a patient
with gastroenteritis without neurological symptoms. It
had previously been shown that GB11 and NCTC 11168
are genetically closely related [14,15,27]. Because of this
relatedness, these strains are very suitable for the detection
of potential GBS-specific markers. HtAFLP analysis of
NCTC 11168 and GB11 generated 241 putative GBS
markers. Overall, 156 of 241 markers could be success-
fully identified with DNA sequencing and BLAST analysis.
A proportion of the marker fragments that were excised
from the gel could not be reliably reamplified and were
excluded from the analysis. Although BLAST searches
were conducted against all DNA sequences in the Pubmed
database, the most significant homology for all AFLP
DNA sequences was with C. jejuni DNA sequences. To fur-
ther reduce this excessive number of putative GBS mark-
ers, we analyzed three additional GBS-associated strains,
not related to the NCTC 11168 and GB11 strains (Cura7,
Cura276 and 260.94; See Additional file 1). This reduced
the number of successfully sequenced putative GBS mark-
ers to 17 (Table 2). Three of these markers were located in
the LOS biosynthesis gene locus. Other genes encoded a
putative periplasmic protein and proteins involved in sig-
nal transduction, metabolism, transport, binding, amino
acid biosynthesis, fatty acid biosynthesis and DNA repli-
cation. Three genes were of unknown function. Markers 5
and 6 displayed distinct restriction site polymorphism
concordant with the AFLP polymorphism. These markers
contained largely overlapping DNA sequences and
showed a complementary pattern of presence and absence
in the GBS-associated and control strains (Table 2). Com-
parison of the DNA sequences revealed that these markers
were based on one DNA polymorphism: the presence of
an additional restriction site in the GBS strains due to a
point mutation (Figure 1).BMC Microbiology 2006, 6:32 http://www.biomedcentral.com/1471-2180/6/32
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Screening of a large strain collection for potential GBS 
markers by PCR-RFLP analysis
After htAFLP analysis of five strains to identify potential
GBS markers, we developed PCR-RFLP tests to screen a
large collection of 27 GBS/MFS-associated and 17 control
enteritis strains for the presence of these markers (for a
survey of these strains see Additional file 1). The strains
used in the htAFLP analysis were also included in the PCR-
RFLP analysis. One randomly selected NCTC 11168 iso-
late was included. Based on the BLAST hit sequences
(Table 2), PCR tests for amplifying 11/17 marker frag-
ments and their flanking regions were developed (See
Additional file 2). Because markers 5 and 6 represented
the same DNA polymorphism, they were included in one
PCR test. Fragments of correct, expected size were pro-
duced with all primer sets. For 5/11 markers a PCR prod-
The basis of the AFLP polymorphism in the complementary markers 5 and 6 Figure 1
The basis of the AFLP polymorphism in the complementary markers 5 and 6 Marker 5 represents a fragment with 
a length of 198 bp that was present in the ht AFLP GBS strains, whereas marker 6, a fragment of 253 bp, was only present in 
the NCTC 11168 isolates. DNA sequence analysis of the GB11 and NCTC 11168 AFLP fragments and subsequent BLAST 
searches showed that both markers were located in gene cj0615, encoding a possible periplasmic protein. Furthermore, DNA 
sequence analysis revealed that a point mutation in the GBS strains had resulted in an additional MboI restriction site, resulting 
the amplification of a shorter AFLP fragment in the GBS strains. Because the selective nucleotide flanking the MboI restriction 
site was identical for the GB11 and NCTC 11168 fragment, the GBS fragments were amplified with the same primerpair as the 
NCTC 11168 fragments. DNA sequences of markers 5 (cj0615_GB11_AFLP) and 6 (cj0615_NCTC 11168_AFLP) are given, as 
well as the NCTC 11168 genome sequence of the same area (cj0615_genomeseq). The AFLP restriction sites are indicated 
with boxes, the selective nucleotides are underscored and the point mutation is indicated in bold.
                       10                  20                  30                  40 
     ------------------+-------------------+-------------------+-------------------+- 
  1  T A A A T T A T T A T G C T A A G A G T T C T A A A C A A T A T A T T A A C A A  cj0615_genomeseq 
  1                                A G A G T T C T A A A C A A T A T A T T A A C A A  cj0615_11168_AFLP 
  1                            T A A G A G T T C T A A A C A A G A T A T T A A C A A  cj0615_GB11_AFLP 
             DdeI 
      
                       50                  60                  70                  80 
     ------------------+-------------------+-------------------+-------------------+- 
 41  T A T T A C T T T A A T A T A T A A C A A T C C T A A A C C A A A T A T T A C A  cj0615_genomeseq 
 26  T A T T A C T T T A A T A T A T A A C A A T C C T A A A C C A A A T A T T A C A  cj0615_11168_AFLP 
 28  T A T T A C T T T A A T A T A T A A C A A T C C T A A A C C A A A T A T T A C A  cj0615_GB11_AFLP 
  
     90                  100                 110                 120 
     ------------------+-------------------+-------------------+-------------------+- 
 81  A A T A T A A A C G A T T T A A A T T T T A A A C A T T A T T T A C T T A C T C  cj0615_genomeseq 
 66  A A T A T A A A C G A T T T A A A T T T T A A A C A T T A T T T A C T T A C T C  cj0615_11168_AFLP 
 68  A A T A T A A A C G A T T T A A A T T T T A A A C A T T A T T T A C T T A C T C  cj0615_GB11_AFLP 
      
                       130                 140                 150                 160 
     ------------------+-------------------+-------------------+-------------------+- 
121  C T G A T A T G A G A G A A G A T G A A G T T C T T T C T T T T A A A G C A A G  cj0615_genomeseq 
106  C T G A T A T G A G A G A A G A T G A A G T T C T T T C T T T T A A A G C A A G  cj0615_11168_AFLP 
108  C T G A T A T G A G A G A A G A T G A A G T T C T T T C T T T T A A A G C A A G  cj0615_GB11_AFLP 
      
                       170                 180                 190                 200 
     ------------------+-------------------+-------------------+-------------------+- 
161  G C A T G G T G T T A A T A C A G C C G G T C A T A G T A T A A A A A C A G T T  cj0615_genomeseq 
146  G C A T G G T G T T A A T A C A G C C G G T C A T A G T A T A A A A A C A G T T  cj0615_11168_AFLP 
148  G C A T G G T G T T A A T A C A G C C G A T C                                    cj0615_GB11_AFLP 
       MboI 
      
                       210                 220                 230                 240 
     ------------------+-------------------+-------------------+-------------------+- 
201  A G A G T G C T T C C T T T T T T A A T C A C A G C A A A A A C C G A T C A T G  cj0615_genomeseq 
186  A G A G T G C T T C C T T T T T T A A T C A C A G C A A A A A C C G A T C        cj0615_11168_AFLP 
                                   MboIBMC Microbiology 2006, 6:32 http://www.biomedcentral.com/1471-2180/6/32
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uct was absent in a variable proportion of strains (Table
3), probably due to primer site sequence heterogeneity.
For example, we have observed previously that gene
cj1136, part of the LOS biosynthesis gene locus and con-
taining marker 7, shows a large degree of DNA sequence
heterogeneity between strains (P. Godschalk, unpub-
lished results). This leads to primer mismatches and
absence of PCR products in a proportion of strains. In 2/
10 PCR tests (markers 7 and 8), the htAFLP GBS-associ-
ated strains could be distinguished from strain NCTC
11168 through the pattern of presence and absence of
PCR products. PCR products for marker 7 were absent in
the GBS-associated strains used in the htAFLP and present
in NCTC 11168, which seemed to be in contrast with the
observation that the original AFLP fragment of marker 7
was present in the GBS strains and absent in NCTC 11168.
However, this apparent inconsistency can be explained by
the fact that the primer sequences of the PCR test were
based on the NCTC 11168 DNA sequence. For marker 7,
a PCR product was seen significantly more frequently in
control enteritis strains (5/27 (18.5%) GBS/MFS strains
versus 9/17 (52.9%) control enteritis strains, P = 0.024).
Next, we subjected the PCR products to a combined diges-
tion with the AFLP restriction enzymes (Table 3). In 4/10
PCR tests (markers 3, 5/6, 9 and 13), the RFLP types were
concordant with the AFLP analysis i.e. the htAFLP GBS-
associated strains shared the same RFLP type whereas
NCTC 11168 displayed a different RFLP type. In 3/10 PCR
tests (markers 11, 12 and 14), the htAFLP GBS-associated
strains did not have identical RFLP types (and for marker
14 there was no PCR product in two GBS strains), but
these RFLP types were also different from that of NCTC
11168. This is not necessarily in contrast with the htAFLP
results, because different RFLP types among the htAFLP
GBS-associated strains may be due to heterogeneity in the
flanking regions of the AFLP fragment. For marker 2, the
RFLP types of the htAFLP strains were not concordant with
the htAFLP polymorphism: the NCTC 11168 and GB11
RFLP types were the same. RFLP types 3 and 4 of marker
9, located in gene cj1139c, were only detected in GBS/
MFS-associated strains (RFLP type 3 or 4 present in 15/27
(55.6 %) GBS/MFS-associated strains versus 0/17 (0%)
enteritis strains, P <0.0001). Although a PCR product for
marker 8, located in gene cj1138, was absent in the major-
ity of strains, RFLP type 1 was more frequently found in
enteritis strains (5/15 enteritis strains versus 1/27 GBS-
associated strains, P = 0.047).
Analysis of South-African GBS-associated and control 
HS:41 strains by htAFLP
In South Africa, serotype HS:41 is over-represented
among GBS-associated strains [10]. Previous studies have
shown that HS:41 strains, both GBS-associated and con-
trols, are highly clonal [12]. As expected, htAFLP of six
GBS-associated, one MFS-associated and six control
HS:41 strains generated very homogeneous banding pat-
terns (results not shown). A total of forty-five AFLP poly-
morphisms were detected, but there were no GBS-specific
Table 1: Polymorphic htAFLP markers for NCTC11168 strains of diverse origin
NCTC11168 
strainsb
11168 hit 
sequenced
markera 123456l e n g t h c Begin end gene and function
1 + + + + - + 469 28753 28317 Cj0023, purB, probable adenylosuccinate lyase
2 - - + - - + 252 67665 67858 Cj0046, probable transmembrane transport protein pseudogene
3 - - + - - - 110 122004 122083 Cj0117, pfs, probable 5'-methylthioadenosine\S-adenosylhomocysteine nucleosidase
4 - - + + + + 118 153984 154075 Cj0150c, probable aminotransferase
5 - - + + + + 86 212438 212383 Cj0227, argD, probable acetylornithine aminotransferase
6 + + + + + - 420 573124 572971 Cj0612c, cft, probable ferritin; Cj0613, pstS, possible periplasmic phosphate binding 
protein
7 - - + + + + 49 589048 589393 Cj0629, possible lipoprotein; Highly similar to Cj1678; Cj1678, possible lipoprotein
8 - - + + + + 382 788562 788468 Cj0840c, fbp, probable fructose-1,6-bisphosphatase
9 - - + - - - 463 104789
1
104832
2
Cj1116c, ftsH, probable membrane bound zinc metallopeptidase
10 - - - + + - 228 122729
6
122712
5
Cj1295, unknown
11 + - - + - - 226 122729
6
122711
7
Cj1295, unknown
1 2 ++-+++ 1 9 1 1 2 7 0 2 9
1
127013
1
Cj1339c, flaA, flagellin A
13 - - + - + + 126 151028
6
151038
1
Cj1580c, probable peptide ABC-transport system ATP-binding protein
aThe individual markers have been given a numerical code. bThe strains are numbered according to Additional file 1. The plusses and minuses 
indicate the presence and absence, respectively, of the AFLP fragments. cThe fragment lengths, based on fragment position in the AFLP gels. dThe 
begin and the end positions in the NCTC 11168 genome are given for all BLAST hits, as well as the corresponding genes and their function.BMC Microbiology 2006, 6:32 http://www.biomedcentral.com/1471-2180/6/32
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markers. Interestingly, 28 AFLP polymorphisms displayed
a similar pattern: fragments were present in the MFS-asso-
ciated strain and two or three control enteritis strains but
absent in the other strains (Figure 2). These fragments
were excised and DNA sequences were determined. BLAST
analysis of five DNA sequences revealed homologies with
various bacterial plasmidal DNA sequences (results not
shown).
Discussion
This study describes a high-throughput AFLP approach for
the detection and identification of DNA polymorphism
and putative GBS-markers in C. jejuni. Previously, we
showed that htAFLP is an excellent tool for assessing the
population structure and the expansion of pathogenic
clones in Staphylococcus aureus and for identification of
genetic polymorphism in the clonal microorganism Myco-
bacterium tuberculosis [26,28]. The optimal enzyme and
selective primer pair combinations are determined by in
silico calculations using the whole genome DNA sequence
of the target microorganism. The optimal number of AFLP
fragments to be generated depends on the aim of the
study. For the detection and identification of potential
disease markers, such as GBS-specific markers in C. jejuni
in the current study, it is desirable to screen the genome
with high resolution. For this, the generation of a large
number of AFLP fragments per strain is needed. Such high
resolution AFLP approach limits the number of strains
that can be analyzed, but this can be overcome by the sub-
sequent analysis of a large number of strains by PCR-RFLP
tests, translated from the potential markers as detected by
the preceding htAFLP analysis. It is, of course, possible
that a disease-specific marker is not detected by htAFLP
because this approach does not result in 100% genome
coverage, which can only be reached with whole genome
sequencing. For C. jejuni, one enzyme combination (MboI
Detail of the htAFLP pattern of the HS:41 strains Figure 2
Detail of the htAFLP pattern of the HS:41 strains A fragment of the banding patterns of the South African HS:41 strains 
is shown. Lane 1–6 GBS-associated strains, lane 7 MFS-associated strain, lane 8–13 enteritis strains. Polymorphic bands repre-
senting plasmidal DNA sequences are indicated with arrows.
         1       2   3               4               5          6    7             8              9         10    11            12            13 
     260.94      233.94      233.95      308.95      367.95     370.95    242.98     378.96    386.96     199.97       250.97     242.97     21.97 BMC Microbiology 2006, 6:32 http://www.biomedcentral.com/1471-2180/6/32
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and DdeI) and 64 different +1/+2 selective primer pair
combinations physically covered approximately 30,000
nucleotides per strain, which represents approximately
2% of the genome.
To find out whether subculturing or storage of C. jejuni
strains leads to the emergence of DNA polymorphism, we
compared 6 isolates of the "genome" strain NCTC 11168
obtained from different laboratories worldwide by
htAFLP analysis. The observed AFLP polymorphisms,
approximately 0.6% of the fragments per strain, could not
be confirmed by PCR-RFLP analysis. This indicates that
the AFLP polymorphisms probably represent the low
background noise of the htAFLP technique and that true
DNA polymorphism could not be detected in the six
NCTC 11168 isolates. The observed background noise
equals a reproducibility of approximately 99.6%, which is
still very high when compared to other genotyping tech-
niques [29].
Recently, two groups described differences in virulence
properties, i.e. the ability to colonise chickens, between
different NCTC 11168 isolates that were not included in
the current study [30,31]. Full transcriptional profiling
revealed expression differences for several gene families in
the NCTC 11168 strains. HtAFLP analysis of the two
NCTC 11168 isolates that were studied by Carrillo et al.
[30,31] failed to identify polymorphisms responsible for
the difference in virulence properties (P. Godschalk and
C. Szymanski, unpublished data). It has to be emphasized
that by htAFLP still only a random proportion of the
genome is screened. DNA sequence variation (such as sin-
gle-nucleotide polymorphisms, SNPs) leading to biologi-
cal differences may therefore not be detected.
Table 2: Putative GBS-markers detected by htAFLP
strainsb 11168 hit 
sequenced
markera 11168 GB11 cura 7 cura 
276
O:41 lengthc begin end gene and function
1 - + + + + 112 324441 324363 Cj0355c, probable two-component regulator
2 +---- 2 6 5 4 0 0 4 9 9 4 0 0 2 6 4 C j 0 4 3 2c, murD, probable UDP-N-
acetylmuramoylalanine – D-glutamate ligase
3 - + + + + 115 575807 575893 Cj0615, pstA, probable phosphate transport 
system permease protein
4 - + + + + 152 576061 576182 Cj0615, pstA, probable phosphate transport 
system permease protein
5 - + + + + 198 904760 904594 Cj0967, possible periplasmic protein
6 + - - - - 253 904817 904596 Cj0967, possible periplasmic protein
7 - + + + + 241 107074
1
107066
2
Cj1136, probable galactosyltransferase
8 +---- 1 3 8 1 0 7 3 1 9
0
107308
2
Cj1138, probable galactosyltransferase
9 - + + + + 97 107426
1
107432
0
Cj1139c, probable galactosyltransferase
10 + - - - - 169 109075
1
109061
2
Cj1157, dnaX, probable DNA polymerase III 
subunit gamma
11 + - - - - 89 109224
5
109218
5
Cj1161c, probable cation-transporting ATPase
12 + - - - - 181 123600
7
123608
0
Cj1306c, unknown
13 + - - - - 137 123640
6
123629
8
Cj1306c, unknown, similar to Cj1310c, Cj1305c, 
Cj1342c, Cj0617/0618
14 + - - - - 438 126418
2
126458
6
Cj1336, unknown, identical to Cj1318 (except the 
C-term)
15 + - - - - 163 132831
1
132818
4
Cj1394, probable fumarate lyase; Cj1393, metC', 
probable cystathionine beta-lyase
16 + - - - - 203 133495
1
133477
9
Cj1400c, fabI, probable enoyl- [acyl-carrier-
protein] reductase [NADH]
17 + - - - - 102 Cj1101, probable ATP-dependent DNA helicase
aThe individual markers have been given a numerical code. bThe plusses and minuses indicate the presence and absence, respectively, of the AFLP 
fragments. cThe estimated fragment lengths on the AFLP gels are given. dThe begin and the end positions in the NCTC 11168 genome are given for 
all BLAST hits, as well as the corresponding genes and their function. Note that markers 5 and 6 are largely overlapping and have a complementary 
pattern of presence and absence (see also Figure 1).BMC Microbiology 2006, 6:32 http://www.biomedcentral.com/1471-2180/6/32
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In search of GBS-specific markers, we first compared the
NCTC 11168 patterns with the AFLP patterns of the genet-
ically related GBS-associated strain GB11. However,
although NCTC 11168 was originally isolated from the
faeces of a patient with gastroenteritis, we cannot exclude
that NCTC 11168 can induce GBS if a patient with the
right host susceptibility factors becomes infected with this
strain. The only substantial but probably very important
difference between NCTC 11168 and GB11 that has been
found so far, is that the LOS biosynthesis gene locus
strongly diverges between these strains, probably as result
of a horizontal exchange event [32]. Comparison of
Table 3: Results of the PCR-RFLP analysis for 11 potential GBS markers identified by htAFLP analysis
marker nr (genomic localization)b
straina disease 2 (cj0432) 3 (cj0615) 5,6 
(cj0967)
7 (cj1136) 8 (cj1138) 9 
(cj1139c)
11 
(cj1161c)
12 
(cj1306)
13 
(cj1306)
14 
(cj1336)
G B 1G B S 1111101221
G B 2G B S 222--1243-
G B 3G B S 222--1233-
G B 4G B S 122--2211-
G B 5G B S 121--3054-
M F 6M F S 222--4260-
M F 7M F S 121--3154-
M F 8M F S 122--0261-
GB11 G B S 122--4275-
G B 1 3 G B S 121100251-
G B 1 5 G B S 1131-02542
G B 1 6 G B S 111--3211-
G B 1 7 G B S 121-00154-
G B 1 8 G B S 222--4246-
G B 1 9 G B S 111--5237-
M F 2 0 M F S 123--5158-
G B 2 1 G B S 222--42053
G B 2 3 G B S 121--40114
G B 2 4 G B S 212---114-
G B 2 5 G B S 12---3158-
G B 2 6 G B S 111--3151-
G B 2 9 G B S 1211--1 1 0 1 0 3
G B 3 0 G B S 3131-31115
cura 7 G B S 222--42853
c u r a  6 9 G B S 222--4239-
cura 276 G B S 222--42853
260.94 G B S 222--4495-
E 9 7 - 0 7 3 7 e n t e r i t i s 1211 n d 0121-
E 9 7 - 0 7 4 7 e n t e r i t i s 1111 n d 025 1 0 5
E 9 7 - 0 7 9 6 e n t e r i t i s 1211-01546
E97-0873 enteritis 2 3 2 - - 0 2 5 nd 4
E 9 7 - 0 9 0 3 e n t e r i t i s 1211-21 1 1 8-
E97-0921 enteritis 1 2 3 - - 6 0 11 6 -
E 9 7 - 0 9 7 4 e n t e r i t i s 121110 n d 514
E 9 7 - 0 9 8 0 e n t e r i t i s 111--5151-
E97-0998 enteritis 2 2 2 - - 7 2 11 nd -
E97-1013 enteritis 1 1 3 - - 5 1 5 10 -
E98-623 enteritis 2 2 2 - - 2 2 5 nd 4
E 9 8 - 6 2 4 e n t e r i t i s 2221-222 n d 7
E 9 8 - 6 8 2 e n t e r i t i s 11111012 1 0-
E 9 8 - 7 0 6 e n t e r i t i s 113--0214-
E 9 8 - 1 0 3 3 e n t e r i t i s 123--1111-
E 9 8 - 1 0 8 7 e n t e r i t i s 121110114-
NCTC 
11168-1
e n t e r i t i s 1111101514
aStrains that were used in the htAFLP are indicated in bold. bThe marker numbers correspond with the marker numbers displayed in Table 3. For 
each marker, the different RFLP types are indicated with numbers. 0 = single band (no restriction), – = no PCR product, nd = not determined.BMC Microbiology 2006, 6:32 http://www.biomedcentral.com/1471-2180/6/32
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NCTC 11168 with GB11 led to the detection of more than
two hundred possible GBS markers, which was substan-
tially higher than the expected background noise of 0.6%,
underscoring the phylogenetic relevance of the polymor-
phisms. The number of possible GBS markers was reduced
to 23 after adding three additional GBS-associated strains.
For 17 markers, the location on the genome could be
identified after DNA sequence analysis. A relatively large
proportion of potential GBS markers (3/17;18%) was
located in the LOS biosynthesis gene locus, whereas this
locus only comprises 1% of the C. jejuni genome (1.64
Mbp). Although this may represent a true pathogenic
association with GBS, it is also possible that htAFLP pref-
erentially picked up the LOS locus because it is a highly
polymorphic region. However, analysis of a larger C. jejuni
strain collection by PCR-RFLP analysis showed that the
three LOS-specific markers were indeed associated with
GBS (marker 7, P = 0.024; marker 8, P = 0.047; marker 9,
P <0.001). These findings are concordant with the pro-
posed pathogenic mechanism of GBS and with previous
reports that certain genes involved in LOS biosynthesis or
specific nucleotide sequences within these genes occur
more frequently in GBS-associated C. jejuni strains [19-
22].
There are several possible explanations for the fact that we
did not find molecular markers that are 100% specific for
the Guillain-Barré syndrome. First, it is possible that truly
GBS-specific features do not exist in C. jejuni. There is a
broad variability in the severity and spectrum of clinical
symptoms in GBS patients [33]. Different ganglioside
mimicking structures and anti-ganglioside antibody spe-
cificities have been associated with certain clinical presen-
tations [34-36], and therefore, C. jejuni markers may be
associated with a subset of various disease entities.
Because of this heterogeneity and the presumed impor-
tance of host-related factors, the existence of features in C.
jejuni that are specific for GBS may be questionable. Sec-
ond, a certain combination of multiple C. jejuni genes
may be required for the induction of GBS. Detection of
such combinations of markers ("polygenic markers") is
extremely labour-intensive and cannot be achieved with
the current approach. Finally, it is possible that htAFLP
failed to detect GBS-specific markers because htAFLP does
not accomplish 100% genome coverage.
One of the three additional GBS-associated strains men-
tioned above was from a collection of South-African
HS:41 strains. In South Africa, the HS:41 serotype is over-
represented among GBS-associated strains [10]. A certain
feature of these strains may be responsible for their capac-
ity to trigger GBS. HS:41 strains were found to be indistin-
guishable by previous genotyping studies, indicating that
HS:41 strains form a genetically stable clone [12]. It is
important to note that the enteritis-only HS:41 strains
may have the same GBS-inducing capacity as the GBS-
associated strains, because host-related factors are also
crucial for developing GBS. We analyzed both GBS-associ-
ated and control enteritis-only HS:41 strains, as well as an
MFS-associated isolate by htAFLP. Although we did not
detect GBS-specific bands, we found that the MFS-associ-
ated isolate and half of the enteritis-only strains contained
several additional fragments that appeared to be linked.
DNA sequences of these fragments showed homologies
with plasmidal DNA sequences, indicating that a subset of
the HS:41 strains contained a plasmid. To our knowledge,
the South African HS:41 strains we used in this study have
never been analyzed for the presence of plasmids.
Whether the presence of a plasmid is of importance for
the virulence or neuropathogenic potential of HS:41
strains currently remains unknown, but seems unlikely
based on the distribution of plasmidal DNA in the tested
strains.
Conclusion
Previous searches for C. jejuni markers for GBS-invoking
potential were unsuccessful when performed with general
genotyping techniques. Some studies that focussed at spe-
cific loci or sometimes even specific genes found poten-
tial, though not absolute, GBS markers within the LOS
biosynthesis genes [19-22]. We have used a method,
htAFLP, that detects sequence polymorphisms in a wide,
non-gene dependent scale. Theoretically approximately
2% of the total genome is covered by this approach. How-
ever, we still conclude that bacterial GBS markers are not
absolute, limited in number and located in the LOS bio-
synthesis gene locus. This corroborates the current con-
sensus that LOS mimicry with human gangliosides may
be the prime etiologic determinant of GBS. In addition to
bacterial factors, host-related factors probably play an
important role in the pathogenesis of GBS as well.
Furthermore, our results demonstrate that htAFLP, with
its high reproducibility and resolution, is an adequate
technique for the detection and subsequent identification
of putative disease and epidemiological markers. Analysis
of a limited number of strains in great detail by htAFLP
and subsequent screening of a large collection of strains
with simple PCR-RFLP tests combines high sensitivity
with the possibility to screen large groups of strains. This
allows for the identification of regions of genomic insta-
bility or variability. Finally, htAFLP does not require com-
plete genome sequences and it is not influenced by the
presence of sequences not present in the genome strain(s).
As such, htAFLP is the second best option, after complete
sequencing of the genome of multiple strains, for the
unbiased detection of genome polymorphisms associated
with pathogenicity or other features of bacterial isolates
from diverse clinical and environmental origin.BMC Microbiology 2006, 6:32 http://www.biomedcentral.com/1471-2180/6/32
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Methods
Bacterial strains, culture conditions and DNA isolation
The C. jejuni strains used for htAFLP analysis are described
in Additional file 1. We collected 6 isolates of the
"genome" strain NCTC 11168 strains from different labs
worldwide [37]. For the detection of potential GBS mark-
ers, we included four C. jejuni strains isolated from the
diarrhoeal stools of GBS patients from different geograph-
ical areas (The Netherlands, Curaçao, South Africa). In
addition, we analyzed a collection of 6 GBS-associated, 1
MFS-associated and 6 enteritis-only HS:41 strains isolated
from South African patients [12]. After identification of
potential GBS markers by htAFLP analysis of these strains,
we screened a larger collection of 27 GBS/MFS-associated
and 17 control strains isolated from enteritis patients with
PCR-RFLP tests for the presence of these markers (See
Additional file 1). C. jejuni strains were cultured for 24–48
hours on blood agar plates in a micro-aerobic atmosphere
at 37°C. DNA was isolated using the Wizard Genomic
DNA Purification Kit (Promega, Madison, WI).
High-throughput AFLP
AFLP analysis was performed essentially as described by
Vos et al. [38]. The optimal enzyme and primer combina-
tions for C. jejuni were determined using the predictive
software package REcomb [39]. Digestion with MboI and
DdeI (Boehringer-Mannheim, Mannheim, Germany) was
combined with the ligation of a specific linker oligonucle-
otide pair (MboI: 5'-CTCGTAGACTGCGTACC-3' and 5'-
GATCGGTACGCAGTCTAC-3'; DdeI: 5'-GACGATGAGTC-
CTGAG-3' and 5'-TNACTCAGGACTCAT-3'). Subse-
quently, a non-selective pre-amplification was performed
using the MboI primer (5'-GTAGACTGCGTACCGATC-3')
and  DdeI primer (5'-GACGATGAGTCCTGAGTNAG-3').
The selective amplifications were performed using differ-
ent linker-specific primer combinations. The 33P-labeled
MboI primer was extended with a single nucleotide (+1),
whereas the DdeI primer was equipped with a 3' terminal
dinucleotide (+2). These nucleotides probe sequence var-
iation beyond that present in the restriction site itself. All
64 possible extension combinations were used. Radioac-
tive labelling was used to enable isolation of DNA frag-
ments from gels for post-AFLP sequencing analysis.
Amplified material was analyzed on 50x30 cm slabgels
and the amplimers were visualized using phosphor-imag-
ing. Post-AFLP, gels were fixed, dried and stored at ambi-
ent temperature.
Marker selection and identification
Marker bands were scored using the automated interpre-
tation software package AFLP QuantarPro (Keygene NV,
Wageningen, The Netherlands), resulting in a binary table
scoring marker fragment absence (0) or presence (1). Pol-
ymorphic marker fragments were validated by visual
inspection of the autoradiographs. Bands differing in sig-
nal intensity were not considered to be polymorphic. A
potential marker for GBS was defined as an AFLP poly-
morphism that discerns the GBS-associated strains from
the NCTC 11168 isolates. Potential GBS marker fragments
can either be present or absent in GBS-associated strains
as compared to NCTC 11168.
Relevant fragments were excised from the gels and re-
amplified using their matching AFLP consensus primer set
without restriction site-specific +1 and +2 extension
sequences attached. The amplimers were subjected to
DNA sequencing using a 96-well capillary sequencing
machine (MegaBACE; Amersham). For fragment identifi-
cation, the DNA sequences were subjected to BLASTn and
BLASTx searches through the NCBI website [40]. BLAST
results enable genomic localization and gene annotation
for the polymorphic marker fragments.
Development of PCR-RFLP tests
PCR-RFLP tests were developed to confirm polymorphism
in the different NCTC 11168 isolates and to screen a col-
lection of C. jejuni GBS/MFS-associated and control
strains. PCR-RFLP tests could only be developed for the
markers of which the localization on the C. jejuni genome
was identified. Forward and reverse primers were
designed (Primer Designer 4, Sci Ed Software, North Caro-
lina) and synthesized, located approximately 50–200 bp
upstream or downstream of the homologous region,
respectively (Table 2). Because of the wide range of melt-
ing temperatures (Tm) of the primers and the sometimes
considerable differences in Tm between primers within
one PCR reaction, a touch-down PCR approach was
applied. The program consisted of 15 cycles of 1 min
94°C, 1 min 70°C minus 1°C for each following cycle
(lowest temperature 55°C), 1 min 72°C, followed by 25
cycles of 0.5 min 94°C, 1 min Tm – 5°C and 1 min at
72°C. Tm – 5°C represents the lowest melting tempera-
ture of the two primers used in the reaction minus 5°C.
This resulted in the amplification of not only the AFLP
fragment itself, but also of their flanking sequences. Next,
15 μl of each PCR product was subjected to a separate or
combined digestion with the restriction enzymes (1 unit/
reaction) used for the AFLP (MboI and DdeI). After over-
night incubation at 37°C, the digests were analyzed on
2% agarose gels. The PCR-RFLP analysis will reveal
whether or not the AFLP variability was due to variation
in the restriction sites (different RFLP patterns) or to inser-
tions or deletions within the AFLP fragment (size differ-
ences in PCR products). AFLP variation due to differences
in the selective extension nucleotides of the AFLP primers
will not be detected using this approach.
Abbreviations
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GBS Guillain-Barré syndrome
HS heat stable
htAFLP high-throughput AFLP
LOS lipo-oligosaccharide
MFS Miller Fisher syndrome
MLST multi locus sequence typing
ORF open reading frame
PCR-RFLP polymerase chain reaction – restriction frag-
ment length polymorphism
PFGE pulsed field gel electrophoresis
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